| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | RISK STRATIFICATION IN INFLUENZA | EP13817599.7 | 2013-07-10 | EP2872891A1 | 2015-05-20 | MCLEAN, Anthony; TANG, Benjamin; PARNELL, Grant, Peter; SHOJAEI, Maryam |
| The present invention relates to methods for the identification of clinical risk in patients having, or suspected of having, influenza. The invention also relates to methods for distinguishing between patients having influenza or viral pneumonia from patients having a symptomatically similar condition. The methods of the invention comprise determination of the level of expression of interferon alpha inducible protein 27 (IF127) in a biological sample from a patient having, or suspected of having, influenza. Kits comprising suitable components for the performance of the methods are also provided by the invention. The invention allows stratification of patients into groups defining clinical risk, for example groups based on the severity of risk to the long-term health of the subject. | ||||||
| 142 | FORMULATIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES | EP97952496.4 | 1997-12-16 | EP0957936B1 | 2006-10-04 | GUPTA, Sunil, K.; MARK, George, E., III |
| Vaccine formulations comprising recombinant early (E) and late (L) proteins of papillomavirus and oxidized mannan as well as methods of making and using the formulations are provided. | ||||||
| 143 | FORMULATIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES | EP97952496 | 1997-12-16 | EP0957936A4 | 2001-09-12 | GUPTA SUNIL K; MARK GEORGE E III |
| 144 | Diagnosis and treatment of bacterial dysentery | EP00101263.2 | 1992-10-19 | EP1018342A3 | 2001-04-11 | Armstrong, Glen D.; Ratcliffe, R. Murray |
There is provided the use of an agent in the preparation of a medicament for the prevention or treatment of an enteric infection mediated by an SLT, wherein said agent is a pharmaceutically acceptable solid inert affinity support capable of being eliminated from the gastrointestinal tract, which support has an affinity ligand covalently attached thereto through a spacer arm, wherein said ligand is characterized as an oligosaccharide containing the disaccharide subunit αGal(1-4)βGal which binds the SLT; |
||||||
| 145 | TREATMENT OF BACTERIAL DYSENTERY | EP92922817.9 | 1992-10-19 | EP0610356B1 | 2001-01-31 | ARMSTRONG, Glen, D.; RATCLIFFE, R., Murray |
| There is provided the use of an agent in the preparation of a medicament for the prevention or treatment of an enteric infection mediated by an SLT, wherein said agent is a pharmaceutically acceptable solid inert affinity support capable of being eliminated from the gastrointestinal tract, which support has an affinity ligand covalently attached thereto through a spacer arm, wherein said ligand is characterized as an oligosaccharide containing the disaccharide subunit alpha Gal(1-4) beta Gal which binds the SLT; with the proviso that the disaccharide is not part of a alpha Gal(1-4) beta Gal(1-4) beta GlcNAc trisaccharide or a alpha Gal(1-4) beta Gal(1-4) beta Glc trisaccharide. | ||||||
| 146 | ASC AND PYRIN-ASC PYROPTOSOMES AND USES THEREOF | PCT/US2008068747 | 2008-06-30 | WO2009014863A9 | 2009-03-26 | ALNEMRI EMAD S |
| The present invention relates to the field of immune responses and to inflammation. Embodiments of the invention relate to methods of: (1) isolating and detecting inflammasomes associated with pyroptosis-ASC pyroptosomes; (2) diagnosing inflammation; (3) detecting pathogen; (4) screening for anti-inflammatory agents; and (5) treatment of auto-inflammatary diseases and disorder. | ||||||
| 147 | ASC AND PYRIN-ASC PYROPTOSOMES AND USES THEREOF | PCT/US2008068747 | 2008-06-30 | WO2009014863A2 | 2009-01-29 | ALNEMRI EMAD S |
| The present invention relates to the field of immune responses and to inflammation. Embodiments of the invention relate to methods of: (1) isolating and detecting inflammasomes associated with pyroptosis-ASC pyroptosomes; (2) diagnosing inflammation; (3) detecting pathogen; (4) screening for anti-inflammatory agents; and (5) treatment of auto-inflammatary diseases and disorder. | ||||||
| 148 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | PCT/US2014045801 | 2014-07-08 | WO2015006355A2 | 2015-01-15 | HONDA KENYA; OLLE BERNAT; ATARASHI KOJI; TANOUE TAKESHI; OHNO HIROSHI; FUKUDA SHINJI; HASE KOJI |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 149 | METHOD FOR DIAGNOSING TUBERCULOSIS DISEASE BY DETECTING INDUCED MARKERS AFTER STIMULATION OF T-CELLS WITH ANTIGENS | PCT/IB2013054377 | 2013-05-27 | WO2013175459A3 | 2014-03-13 | WALZL GERHARD; CHEGOU NOVEL NJWEIPI; NDONG PAULIN ESSONE |
| A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-a, TNF- a, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-a2, fractalkine, IFN-gamma, IL-13, IL-1 Ra, IL-3, IL-4, IL-5, MIP-1 a, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1 beta, IL-6, GM-CSF, IL-1 a, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-beta, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject. | ||||||
| 150 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | PCT/US2014045801 | 2014-07-08 | WO2015006355A3 | 2015-11-26 | HONDA KENYA; OLLE BERNAT; ATARASHI KOJI; TANOUE TAKESHI; OHNO HIROSHI; FUKUDA SHINJI; HASE KOJI |
| Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent. | ||||||
| 151 | METHOD FOR REDUCING ADHESION OF MICROORGANISMS TO FABRICS | PCT/EP2014078383 | 2014-12-18 | WO2015091740A3 | 2015-10-22 | KATZENMEIER HEINZ; STUTTE PETER; SCHMIDT-EMRICH SABRINA; THÖNY-MEYER LINDA; ZULIAN QUN REN |
| The invention relates to a method for finishing fibers and/or fabrics with the aim of reducing adhesion of microorganisms, in particular bacteria and/or yeasts, to the fibers and/or fabrics. The disclosed method involves applying a composition (ZS) containing selected hydrophilic silane derivatives to the fibers and/or fabrics. The invention further relates to a method for quantitatively determining the adhesion of microorganisms to fibers and/or fabrics. | ||||||
| 152 | ANTIBODIES DIRECTED AGAINST INFLUENZA | PCT/US2012060912 | 2012-10-18 | WO2013059524A3 | 2013-06-13 | AHMED RAFI; WRAMMERT JENS; WILSON PATRICK C |
| Antibodies that specifically bind influenza virus hemagglutinin A (HA), and antigen binding fragments thereof are disclosed herein. In several embodiments, these antibodies are broadly neutralizing. Nucleic acids encoding these monoclonal antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed. Compositions are disclosed that include these antibodies, antigen binding fragments, nucleic acids, vectors and host cells. Method of using these antibodies, and antigen binding fragments, nucleic acids, vectors and host cells, such as for diagnosis and treatment of an influenza virus infection are also provided. | ||||||
| 153 | METHOD AND APPARATUS FOR DETECTION OF MULTIPLE BIOLOGICAL MATERIALS WITH A HETEROGENEOUS ANTIBODY MIXTURE | PCT/US0212041 | 2002-04-15 | WO02084251A3 | 2003-07-10 | BODENHAMER WILLIAM |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
| 154 | METHOD AND APPARATUS FOR SELECTIVE BIOLOGICAL MATERIAL DETECTION | PCT/US0112477 | 2001-04-16 | WO0179850A3 | 2002-12-19 | BODENHAMER WILLIAM T |
| The present invention relates to bioassay materials useful for the detection of toxic substances and, more particularly, to packaging materials for food and other products, along with methods for their manufacture and use. The invention provides a unique composite material capable of detecting and identifying multiple biological materials within a single package. The biological material identification system is designed for incorporation into existing types of flexible packaging material such as polyvinylchloride or polyolefin films, and its introduction into the existing packaging infrastructure will require little or no change to present systems or procedures. | ||||||
QQ群二维码
意见反馈
意见反馈